We deliver high-quality solutions to assess translational control of gene expression and translatome-associated biomarkers.
The Ribosome Company
Immagina BioTechnology has developed RiboLace™, an antibody-free technology for the analysis of biologically relevant macromolecules by selectively isolating native and active polyribosomes. RiboLace™ is the first technology to capture only the active fraction of mRNA being translated, which is the actual measure of which proteins are being produced. RiboLace™ provides a snapshot of protein expression for an accurate picture of what a cell is manufacturing and insights into its pathological state.
Immagina’s ambition is to deliver smart solutions for truer gene expression analysis in research and hospital labs, to support life science worldwide.
We are working to provide you with the best picture of gene expression.
Immagina BioTechnology has developed unique, user-friendly, low cost, highly processive and versatile tools for the purification and analysis of polyribosomes.
Our RiboLace™ technology gives a snapshot on protein expression for an accurate picture of what a cell is manufacturing. RiboLace™ is embedded in two products for (1) more accurate gene expression analysis and (2) better ribosome profiling studies.
We are engaged with customers at every step of the way.
Immagina BioTechnology is a StartUp hosted in the Laboratory for Biomolecular Sequence and Structure Analysis for Health (LaBSSAH), a hub comprising private and public institutions: the Bruno Kessler Foundation (FBK), the Institute of Biophysics of the Italian National Research Council (CNR-IBF) and the Centre for Integrative Biology of the University of Trento (CIBIO).
Immagina represents a unique opportunity to synergistically match the academic know-how and industrial needs.
If you are ready to make your mark with a company that’s striving to make an impact in the lives of millions, join Immagina. We’re dedicated to advanced medicines and innovative healthcare, starting from a better understanding of gene expression at the ribosomal level. If you are wishing to embark on a career in a fast-evolving company, Immagina offers two career opportunities that will develop your talents, and allow you to contribute to breakthrough innovation in the fields of RNA/ribosome targeted small molecule and selective capture of active ribosomes. Open positions:
Please send Curriculum vitae, a letter describing your interest and contact details of three references to email@example.com. We will hold on to your resume and contact you only if your profile meets our needs.
I. Immagina is growing. Seed funding was obtained in 2017. In 2018 the company raised a total of € 1M to rapidly expand the portfolio of products and the intellectual property.
II. 28th November 2016. Immagina Biotechnology s.r.l. raises € 0.48 million. This is the first joint investment in start-up held by business angels from the entire Euregio. We thank the new shareholders, Harald Oberrauch (Technicon S.p.A.) and Hermann Hauser Investment Gmbh for sharing our vision!
III. In Jan 2016 Immagina BioTechnology got new private fundings from local italian investors. We thank our Business Angels for trusting our technology and our business model.
IV. Our project called RiboTIP (PolyRibosomes on microplaTes for Innovative Products) developed in collaboration with the National Research Council has been granted 60.000 Euro from the CARITRO Foundation. We thank the Foundation for trusting our technology and business culture aimed at an innovative local development. For more information click here.
V. We thank Biomat s.r.l. for the kind support on microplates engineering.